Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB

Nature Medicine

Volumn 11, Issue 2, 2005, Pages 183-190

  Cai, Dongsheng ^a   Yuan, Minsheng ^a   Frantz, Daniel F ^a,b   Melendez, Peter A ^a,c   Hansen, Lone ^a   Lee, Jongsoon ^a   Shoelson, Steven E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c Hewlett Packard Caribe Ltd   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; SALICYLIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; LIVER; LIVER CELL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARBOHYDRATE METABOLISM; CYTOKINES; DIETARY FATS; FEMALE; HEPATOCYTES; HUMANS; I-KAPPA B KINASE; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B; OBESITY; PROTEIN-SERINE-THREONINE KINASES; RATS; SALICYLATES; SIGNAL TRANSDUCTION;

EID: 14644427890     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1166     Document Type: Article

References (45)

1. Mokdad, A.H. et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 76-79 (2003),
2. nd edition (National Institutes of Diabetes and Digestive Diseases, National Institutes of Health, Bethesda, Maryland, 1995).
3. Boden, G. & Shulman, G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Invest. 32 Suppl 3, 14-23 (2002).
4. Seppala-Lindroos, A. et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87, 3023-3028 (2002).
5. Ryysy, L. et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49, 749-758 (2000).
6. Kelley, D.E., McKolanis, T.M., Hegazi, R.A., Kuller, L.H. & Kalhan, S.C. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am. J. Physiol. 285, E906-E916 (2003).
7. Pickup, J.C. & Crook, M.A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41, 1241-1248 (1998).
8. Barzilay, J.I. & Freedland, E.S. Inflammation and its relationship to insulin resistance, type 2 diabetes mellitus, and endothelial dysfunction. Metabolic Syndrome 1, 55-67 (2003).
9. Festa, A., D'Agostino, R., Jr., Tracy, R.P. & Haffner, S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51, 1131-1137 (2002).
10. Hotamisligil, G.S. Inflammatory pathways and insulin action. Int. J. Obes. Relat. Metab. Disord. 27 Suppl 3, S53-S55 (2003).
11. Moller, D.E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 11, 212-217 (2000).
12. Yuan, M. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673-1677 (2001).
13. Hundal, R.S. et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109, 1321-1326 (2002).
14. Radziuk, J. Insulin sensitivity and its measurement: structural commonalities among the methods. J. Clin. Endocrinol. Metab. 85, 4426-4433 (2000).
15. Hotamisligil, G.S., Shargill, N.S. & Spiegelman, B.M. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
16. Feinstein, R., Kanety, H., Papa, M.Z., Lunenfeld, B. & Karasik, A. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 268, 26055-26058 (1993).
17. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E. & Ridker, P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327-334 (2001).
18. Spranger, J. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52, 812-817 (2003).
19. Kanemaki, T. et al. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27, 1296-1303 (1998).
20. Klover, P.J., Zimmers, T.A., Koniaris, L.G. & Mooney, R.A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52, 2784-2789 (2003).
21. Rotter, V., Nagaev, I. & Smith, U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278, 45777-45784 (2003).
22. Lagathu, C. et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun. 311, 372-379 (2003).
23. Kim, H.J. et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53, 1060-1067 (2004).
24. Delhase, M., Hayakawa, M., Chen, Y. & Karin, M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 284, 309-313 (1999).
25. Mercurio, F. et al. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol. Cell Biol. 19, 1526-1538 (1999).
26. Ling, L., Cao, Z. & Goeddel, D.V. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. USA 95, 3792-3797 (1998).
27. Starnes, H.F., Jr. et al. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J. Immunol. 145, 4185-4191 (1990).
28. Abrams, J.S. et al. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol. Rev. 127, 5-24 (1992).
29. Haddad, E. et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97, 1590-1597 (2001).
30. Shoelson, S.E., Lee, J. & Yuan, M. Inflammation and the IKKβ/κB/NF-κB axis in obesity- and diet-induced insulin resistance. Int. J. Obes. Relat. Metab. Disord. 27 Suppl 3, S49-S52 (2003).
31. Van Antwerp, D.J., Martin, S.J., Kafri, T., Green, D.R. & Verma, I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274, 787-789 (1996).
32. Weisberg, S.P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003).
33. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, J. Clin. Invest. 112, 1821-1830 (2003).
34. Cai, D. et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 119, 285-298 (2004).
35. Rohl, M. et al. Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. J. Clin. Invest. 113, 474-481 (2004).
36. Shoelson, S. Invited comment on W. Ebstein: on the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J. Mol. Med. 80, 618-619 (2002).
37. Marchesini, G. et al. Metformin in non-alcoholic steatohepatitis. Lancet 358, 893-894 (2001).
38. Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., Oliver, D. & Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38, 1008-1017 (2003).
39. Promrat, K. et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39, 188-196 (2004).
40. Brinster, R.L., Allen, J.M., Behringer, R.R., Gelinas, R.E. & Palmiter, R.D. Introns increase transcriptional efficiency in transgenic mice. Proc. Natl. Acad. Sci. USA 85, 836-840 (1988).
41. DiDonato, J.A., Mercurio, F. & Karin, M. Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol. Cell Biol. 15, 1302-1311 (1995).
42. Li, N. & Karin, M. Signaling pathways leading to nuclear factor-kappa B activation. Methods Enzymol. 319, 273-279 (2000).
43. Burant, C.F. et al. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100, 2900-2908 (1997).
44. Kim, J.K. et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 108, 437-446 (2001).
45. Weibel, E.R. Sterelogical Methods. Academic Press, London (1979).